All posts by medical

Inflammatory Mediator Could Be Targeted To Treat Pneumonia – Technology Networks

Researchers at Karolinska Institutet in Sweden report that a recently discovered inflammatory mediator, interleukin-26, appears to have an important role in pneumonia and contribute to the killing of bacteria. The study is published in the scientific journalFrontiers in Immunology - Microbial Immunology.Bacterial lung infection affects both children and adults worldwide and pneumonia remains a common cause of premature death in many parts of the world, with millions of people dying from it every year. To facilitate the development of more effective therapies, researchers at Karolinska Institutet are trying to characterise the immunological mechanisms involved in pneumonia.

The new study demonstrates that an inflammatory mediator called interleukin-26 (IL-26) is critically involved in bacterial pneumonia in humans. During the last decade, IL-26 has emerged as an important player in the so-called innate immune response, our first line of defence against pathogens. It is abundant in the airways of healthy humans, and bacterial exposure stimulates an increased release of IL-26 by lung cells and white blood cells.

Studying human lung tissue and airway samples from patients with bacterial pneumonia, the researchers were able to show that IL-26 exerts complex modulatory effects on the immune system and that the protein directly kills bacteria known to cause pneumonia.

Antibiotics are not sufficient to treat pneumonia and antibiotic resistance is an increasing problem, highlighting the need for biological treatments of this global killer disease. Our findings position IL-26 as a new potential target for biological treatment and emphasise that its role in pneumonia deserves to be further evaluated, says lead author Karlhans Che, a researcher at the Institute of Environmental Medicine, Karolinska Institutet.

The research was financed by the Swedish Heart-Lung Foundation, The Swedish Research Council, Region Stockholm (ALF funding), and The Swedish Society for Medical Research. The authors declare that there is no conflict of interest.

Reference:Che KF, Paulsson M, Piersiala K, et al. Complex involvement of interleukin-26 in bacterial lung Infection. Front. Immunol. 2021;12:4531. doi: 10.3389/fimmu.2021.761317

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Excerpt from:
Inflammatory Mediator Could Be Targeted To Treat Pneumonia - Technology Networks

Merck and Synthekine Strike $525 Million Cytokine Therapy Deal – BioSpace

Merckis widening its reach into the treatment of autoimmune diseases by investing inSynthekine, a bioresearch company that develops engineered cytokine therapeutics.

Under a worldwidecollaboration and research agreement, Merck can exclusively take advantage of Synthekine's surrogate cytokine agonist platform to discover, develop, and sell new cytokine-based treatments for up to two cytokine targets. The companies will first look into potential therapies for autoimmune illnesses but can later go into immunology, oncology, and other indications.

Cytokines are small proteins that are essential to immune homeostasis, but developing them to create therapies can be tricky due to their pleiotropic nature. Trying to harness them for treatment often leads to "wild-type" products that have either dose limiting toxicities or low efficacy. However, using Synthekine's technology, cytokine agonists can dimerize or multimerize cytokine receptors properly, resulting in a wide range of biased and selective signaling potential.

"At Synthekine, we are focused on advancing cytokine science through three protein engineering platforms to create optimized therapeutics in this important space. Our surrogate cytokine agonist platform produces a new class of cytokine therapeutics that are designed to deliver selective immunotherapies for the treatment of autoimmune diseases and cancer," said Debanjan Ray, chief executive officer of Synthekine, in a statement.

Merck will pay Synthekine upfront, plus another one-time payment if a second target is identified. Synthekine stands to receive as much as $525 million in milestones and royalties from net sales for every target achieved. Funding for research will also come from Merck.

"Emerging insights from immunology and oncology are providing new and different ways to think about treating diseases. We look forward to collaborating with Synthekine to evaluate new approaches to harness the therapeutic potential of cytokines," added Dr. Dean Y. Li, the president of Merck Research Laboratories.

Just a few days ago, Synthekine announced that the U.S. Food and Drug Administrationapproved its investigational new drug (IND) application forSTK-012, an IL2 partial agonist that has the potential for use as monotherapy or in combination with immune checkpoint inhibitors to treat advanced solid tumors. STK-012 has the ability to stimulate antigen-activated T cells, which are linked with anti-tumor activity while avoiding the stimulation of toxicity-causing killer cells.

IL-2 is a cytokine with proven benefit as an anti-cancer therapy. However, the indiscriminate activity of IL-2 can cause severe toxicities, limiting its clinical application. We have designed STK-012 to uncouple the efficacy and toxicity of IL-2, and we look forward to now investigating its potential in our first clinical development program," noted Naiyer Rizvi, M.D., the chief medical officer of Synthekine, in a separate press release.

Synthekine is expected to begin its clinical investigation for SK-012 soon.

Go here to read the rest:
Merck and Synthekine Strike $525 Million Cytokine Therapy Deal - BioSpace

Pfizer bows out of the Tyk2 race – Vantage

2021 had once looked like the year of the Tyk2 inhibitors, but some shine is coming off this member of the Jak family. Pfizer today disclosed plans to offload two projects with activity against Tyk2, not long after the lead proponent of this approach, Bristol Myers Squibb, reported disappointing data with deucravacitinib in ulcerative colitis. Pfizer did not give a reason for its Tyk2 exit, which will see brepocitinib and PF-06826647 licensed to a new company that Pfizer is forming in partnership with an unnamed autoimmune player; the pharma giant will have a 25% stake in this venture and retain certain ex-US rights. Perhaps the decision was spurred by toxicity concerns with the Jak inhibitors, which solidified in September into a class warning; however, Pfizer is keeping hold of its Jak1 abrocitinib which is still awaiting an FDA decision in atopic dermatitis and the Jak3/Tec inhibitor ritlecitinib. Still, other mechanisms now look like a priority: Pfizer highlighted several immunology projects in its third-quarter presentation, including a high potency topical PDE4 inhibitor, PF-07038124, for atopic dermatitis and psoriasis; PF-06480605, a TL1A inhibitor for ulcerative colitis; and the interferon-beta Inhibitor PF-06823859 in dermatomyositis.

Originally posted here:
Pfizer bows out of the Tyk2 race - Vantage

Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021 – marketscreener.com

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its third quarter 2021 financial results on Monday, November 8, 2021.

In connection with the earnings release, Gossamers management team will host a live conference call and webcast at 4:15 p.m. ET on Monday, November 8, 2021, to discuss the Companys financial results and provide a corporate update.

Conference ID: 9749597Domestic Dial-in Number: (833) 646-0603International Dial-in Number: (929) 517-9782Live Webcast: https://edge.media-server.com/mmc/p/sezfo9jk

A replay of the audio webcast will be available for 30 days on the Investors section of the Company's website, http://www.gossamerbio.com.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211102006184/en/

See the original post here:
Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021 - marketscreener.com

Rising to the COVID-19 Challenge: Using Preclinical Models to Assess Vaccines and Antivirals, Upcoming Webinar Hosted by Xtalks – PR Web

SRI International has utilized their biosafety level 3 (BSL3) facilities and mobilized its virology and immunology groups to develop preclinical and in vitro COVID-19 models.

TORONTO (PRWEB) November 02, 2021

Given the enormity of the COVID-19 pandemic, researchers are pursuing multiple drug, immune therapy and vaccine development strategies. SRI, as one of NIHs leading preclinical partners, has a long history of rapid response to critical issues like COVID-19. To help address this new viral challenge, SRI International has utilized their biosafety level 3 (BSL3) facilities and mobilized its virology and immunology groups to develop preclinical and in vitro COVID-19 models.

Using these novel models, they have the ability to test novel antiviral approaches against multiple SARS-CoV-2 strains, including the Delta strain. For example, they can partner with a wide variety of companies to screen their novel biologics for activity against SARS-CoV-2 variants in their own in vitro assays. Within months of the pandemic, SRI scientists determined in vivo LD50 infection curves and used these parameters to best assess anti-viral compounds.

These assays can generate realistic data to guide the development of robust antiviral approaches to eliminate the pandemic threat. SRI is working with scientists from around the world to create practical antiviral treatments that will be used for years. Additionally, they are working to develop and validate rapid in vitro testing platforms to screen for SARS-CoV-2 exposure and infection.

Join Mary Lanier, PhD, Director of Immunology and Virology, SRI Biosciences, A Division of SRI International, in a live webinar on Thursday, November 18, 2021 at 1pm EST (10am PST) to hear more about these preclinical models including the data they have generated and how they are working with partners to improve preclinical modeling for COVID-19 therapeutics and vaccines.

For more information, or to register for this event, visit Rising to the COVID-19 Challenge: Using Preclinical Models to Assess Vaccines and Antivirals.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.comFor information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Continued here:
Rising to the COVID-19 Challenge: Using Preclinical Models to Assess Vaccines and Antivirals, Upcoming Webinar Hosted by Xtalks - PR Web

Putting Brains on the Witness Stand – The Regulatory Review

Neuroscientific evidence in the courtroom may test judges and standards of admissibility.

As the United States continues to bear witness to high-profile episodes of police violence, many have wondered: What was that officer thinking?

Although it might seem as if we can never know for sure, neuroscience has already entered criminal courtrooms, with some lawyers extolling the disciplines ability to peer into the subconscious. According to its proponents, neuroscientific evidence has the potential to promote just outcomes by making it easier to determine whether someone is lying.

Skeptics argue that neuroscientific evidence presents a host of concerns, including privacy and due process rights. Many neuroscientists point to a more basic issue.

Despite advances in understanding the human brain, neuroscience has yet to decipher the workings of mind. Technologies exist that produce accurate inferences about what someone is thinking. But devices that can actually read intentions and memoriesdevices that could probe a violent police officers mindare still the stuff of science fiction. For now, it largely remains up to judges to regulate what kinds of neuroscientific evidence make it into court.

The most common kind of neuroscientific evidencesometimes called neurobiological evidenceis information about a defendants brain health and function. This information usually takes the form of brain scans, neuropsychological tests, or medical history records. A physician or other expert can testify that a particular scan, test, or record indicates that a defendant is physically unable to form the requisite intent for the charged offense or as mitigating evidence at sentencing.

The connection between neurobiological evidence and the ultimate issue of a defendants mental state raises difficult questions. For example, even though a brain scan may be able to show, with high accuracy, that a certain defendant has significant brain damage, does this mean that the defendant is legally insane? The answer may depend on the location and extent of the brain damage, but it will also depend on how the judge construes the definition of legal insanity. Can the legal concept of recklessness be matched with a specific pattern of brain activity? Should neuropsychological tests influence determinations of a teenagers culpability?

Forensic neuroscience may present even thornier questions. This variety of neuroscientific evidence derives from EEG-based technologies which measure specific brain signals associated with memory recognition to detectat least in theorywhether a suspect has hidden knowledge of a crime. After decades on the fringe of neuroscience, brain fingerprinting may be poised to attain mainstream status in the near future.

It is largely up to trial judges to untangle these questions about the proper role of neuroscience in the courtroom. In the United States, the Federal Rules of Evidence and their state law counterparts regulate kinds of information that lawyers can introduce at trial. Expert testimony, such as neuroscientific evidence, is further governed by standards derived from two U.S. Supreme Court cases: Daubert v. Merrell Dow Pharmaceuticals and Frye v. United States. Both standards serve as guidelines for weeding out unreliable scientific, technical, or otherwise specialized evidence.

The Daubert standard obliges judges to look at factors such as whether the method or theory used to generate the evidence has been tested, whether there is published peer-reviewed work about it, its error rate, whether there are any standards of operation, and whether it is generally accepted in the relevant field. Federal courts and many states use the Daubert standard.

Some states retain the older Frye standard, which simply requires judges to determine whether the method or theory is generally accepted in the relevant field. Of course, judges must also determine whether experts are qualified and whether their information is helpful to the trier of fact.

Many kinds of neurobiological evidencescans, tests, and medical recordshave a good chance of satisfying the Daubert test. They are well-validated, the subject of peer-reviewed work, tend to have low error rates, and have extensive and detailed standards of operation. Even brain fingerprinting may stand a chance; one U.S. court has already admitted it as evidence in a criminal case.

Yet Daubert, Frye, and related evidence rules have failed to catch faulty scientific evidence. In 2009, the National Academy of Sciences released a report calling for a reevaluation of commonly admitted forensic techniques, such as bite mark and fingerprint analyses. Despite widespread belief in their reliability, the Academy report indicated that few had solid scientific foundations. Indeed, over a hundred people convicted on the basis of these unreliable techniques have been exonerated.

Since the reports publication, various states and organizations have taken steps to remedy the use of bad science in criminal cases. Under Daubert and Frye, however, trial judges remain the final arbiters of what constitutes acceptable expert testimony. The Supreme Court has clarified that appellate courts should review decisions on the admissibility of expert testimony for abuse of discretiona low bar to clear.

Most neuroscientific evidence does rest on solid scientific foundations. And some studies have found that jurors, once thought to be easily swayed by the mere hint of science, may not find information about a defendants brain especially persuasive.

Since neurolaw is still an infant field, little empirical research exists on the potential limits and risks of putting brains on the witness stand for experts (and judges) to draw upon. Even if the science itself is not faulty, lawyers may call experts who overstate what that science can prove or frame a hotly debated opinion as the fields consensus.

These issues may not be unique to neuroscientific evidence. Toxic tort litigation, for example, is often a battle of the experts. Nevertheless, neuroscientific evidence carries distinctive risks. Being able to uncover that police officers memoriesor those of a robbery witness, or a teenage defendantcould be the difference between guilty and not guilty. That is a lot of stress to put on judges brains.

Here is the original post:
Putting Brains on the Witness Stand - The Regulatory Review

Neuroscience research finds brain structure differences in men and women are not strongly linked to behavioral differences – PsyPost

Brain structure differences in men and women are only weakly linked to behavioral differences, according to new research that analyzed two large independent brain imaging datasets. The findings have been published in the journal Psychological Science.

The presence of sex differences in human behavior is well documented, but whether these behavioral differences are related to differences in male and female brain structure has been unclear. Previous research has indicated that sex differences in brain structure are, in fact, related to sex differences in behavior. But the new findings provide evidence that this relationship is mostly driven by brain size.

My background in neuropsychology and neuroimaging made me interested in this topic, i.e., whether sex differences in the brain are related to sex differences in behavior, explained study author Liza van Eijk, a psychology lecturer at James Cook University.

Sex differences have been found for behavior, for example, on average better visuospatial skills for males than females, and vice versa, on average better empathy skills found for females than males. Sex differences have also been found for disease and mental disorders, such as the higher prevalence for autism spectrum disorder in males vs. females, and vice versa, higher prevalence for depression in females vs. males.

In addition, several sex differences have been found in the brain, such as that male brains are on average 10-15% larger than female brains. The question that remained was whether sex differences in behavior could be related to sex differences in the brain, and if so, this relationship could provide insights for disorders that have shown sex differences.

The researchers used data from the Human Connectome Project and the Queensland Twin IMaging Study to examine individual differences in male and female brain structure. Both the Human Connectome Project and Queensland Twin IMaging Study used high-quality imaging technology to measure brain structure.

The studies also collected a variety of physical, neurocognitive, and behavioral data from participants, including but not limited to body mass index, intelligence, working memory performance, personality traits, and psychiatric symptoms. The combined sample included data from 2,153 adults.

To eliminate societal and cultural factors that could influence sex differences in behavior, van Eijk and her colleagues examined brain differences among individuals of the same-sex. In other words, they separately compared women to other women and compared men to other men.

Considering that women and men are subject to differential societal and cultural norms, we examined individual differences in brain structure along a male-female dimension, separately for each sex, van Eijk told PsyPost.

Depending on differences in genetic predispositions as well as exposure and sensitivity to sex hormones, some men will develop a more female-like brain whereas other men will develop a more male-like brain, and vice versa for women. Next, we also examined behavioral differences (such as personality and cognition) along a male-female dimension. Then, we looked at whether these brain and behavioral differences along a male-female dimension were related to one another.

The researchers found a statistically significant association between brain differences and behavioral differences, but the association disappeared after accounting for differences in brain size.

We (only) found a weak relationship between brain and behavioral sex differences, showing that brain structure differences in men and women are not strongly linked to behavioral differences and that likely many other factors play a role in behavioral sex differences, van Eijk explained. In addition, the weak relationship was mostly explained by differences in brain size, suggesting that future research examining the link between brain and behavior needs to carefully consider differences in brain size.

The study included a number of strengths, including its relatively large sample size. But, as with all research, the findings include a few caveats.

This is a correlational study, so therefore we cannot conclude anything about the direction of the effect, van Eijk told PsyPost. Further research is needed to determine whether sex (but also gender) differences in brain and behavior are the result of a common factor (e.g. masculinization of the brain early during gestation) and/or whether sex differences in the brain influence behavior, and/or vice versa, how these differences in behavior influence the brain.

In addition, it is unclear whether this relationship between sex differences in brain and behavior changes across the lifespan, in particular of interest are periods such as puberty and menopause, periods characterized by significant changes in sex hormone levels.

I believe it is important not to ignore sex differences in research, no matter how small, as examining these could provide new clues for behavior and disease showing sex differences in their prevalence or symptom expression, van Eijk added. However, it is important to acknowledge that individual differences are often larger than the sex differences observed and that sex differences found (whether in brain or behavior) do not provide any evidence for which sex is most superior.

The study, Are Sex Differences in Human Brain Structure Associated With Sex Differences in Behavior?, was authored by Liza van Eijk, Dajiang Zhu, Baptiste Couvy-Duchesne, Lachlan T. Strike, Anthony J. Lee, Narelle K. Hansell, Paul M. Thompson, Greig I. de Zubicaray, Katie L. McMahon, Margaret J. Wright, and Brendan P. Zietsch.

Read more:
Neuroscience research finds brain structure differences in men and women are not strongly linked to behavioral differences - PsyPost

How does the brain create our perception of reality? – EurekAlert

WASHINGTON, D.C. New findings from studies in both people and animals are revealing clues about how sensory information and cognitive processes interact in the brain to produce our perception of the world. The findings were presented at Neuroscience 2021, the annual meeting of the Society for Neuroscience and the worlds largest source of emerging news about brain science and health.

Sensory inputs, such as sights, sounds, and touches, yield rich information about the external world. But our perception and interpretation of sensations are heavily shaped by cognitive processes such as attention, expectation, and memory. A better understanding of the neural basis of perceptual phenomena will help clarify both ordinary experiences such as the ability to pick a single voice out of a noisy background and disorders in which perception is altered such as attention-deficit/hyperactivity disorder, autism, schizophrenia, and Alzheimers disease.

Todays new findings show:

The neuroscience findings presented today demonstrate the importance of comparative brain studies in long-standing issues in human perception and cognition, said Sabine Kastner, a professor at Princeton University who studies visual perception and attention. These advances show how research in different model systems can come together to inform our understanding of the human brain, from the neurobiological mechanisms of perception to our subjective perceptual experiences.

This research was supported by national funding agencies including the National Institutes of Health and private funding organizations. Find out more about sensory perception and the brain on BrainFacts.org.

Mechanisms of Perception Press Conference Summary

PV Neurons Enhance Cortical Coding in the Cocktail Party Problem

Kamal Sen, kamalsen@bu.edu, Abstract P442.10

Body Ownership and the Neural Processes of Memory Encoding and Reinstatement

Heather Iriye, heather.iriye@ki.se, Abstract P505.02

The Neural Bases of Simulation in the Primate Brain

David Sheinberg, David_Sheinberg@brown.edu, Abstract P775.01

Closed-loop EEG-TMS Modulation of Frontal-occipital Communication Enhances Visual Perception

Nitzan Censor, censornitzan@tauex.tau.ac.il, Abstract P767.09

###

About the Society for Neuroscience

The Society for Neuroscience is the world's largest organization of scientists and physicians devoted to understanding the brain and nervous system. The nonprofit organization, founded in 1969, now has nearly 37,000 members in more than 90 countries and over 130 chapters worldwide.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Go here to see the original:
How does the brain create our perception of reality? - EurekAlert

Harvard Neuroscientists Explore the Science of Acupuncture – SciTechDaily

Researchers have discovered neurons needed for acupunctures anti-inflammatory response,

Acupuncture is a traditional Chinese technique that has been used for millennia to treat chronic pain and other health problems associated with inflammation, yet the scientific basis of the technique remains poorly understood.

Now, a team of researchers led by neuroscientists at Harvard Medical School has elucidated the underlying neuroanatomy of acupuncture that activates a specific signaling pathway.

In a study conducted in mice and published October 13, 2021, in Nature, the team identified a subset of neurons that must be present for acupuncture to trigger an anti-inflammatory response via this signaling pathway.

The scientists determined that these neurons occur only in a specific area of the hindlimb regionthus explaining why acupuncture in the hindlimb works, while acupuncture in the abdomen does not.

This study touches on one of the most fundamental questions in the acupuncture field: What is the neuroanatomical basis for body region, or acupoint, selectivity? said lead investigator Qiufu Ma, HMS professor of neurobiology at Dana-Farber Cancer Institute.

One area of particular interest to the research team is the so-called cytokine stormthe rapid release of large quantities of cytokines that frequently drives severe, systemic inflammation, and can be triggered by many things, including COVID-19, cancer treatment, or sepsis.

This exuberant immune response is a major medical problem with a very high fatality rate of 15 percent to 30 percent, Ma said. Even so, drugs to treat cytokine storm are lacking.

In recent decades, acupuncture has been increasingly embraced in Western medicine as a potential treatment for inflammation.

In this technique, acupoints on the bodys surface are mechanically stimulated, triggering nerve signaling that affects the function of other parts of the body, including organs.

In a 2014 study, researchers reported that electroacupuncture, a modern version of traditional acupuncture that uses electrical stimulation, could reduce cytokine storm in mice by activating the vagal-adrenal axisa pathway wherein the vagus nerve signals the adrenal glands to release dopamine.

In a study published in 2020, Ma and his team discovered that this electroacupuncture effect was region specific: It was effective when given in the hindlimb region, but did not have an effect when administered in the abdominal region. The team hypothesized that there may be sensory neurons unique to the hindlimb region responsible for this difference in response.

In their new study, the researchers conducted a series of experiments in mice to investigate this hypothesis. First, they identified a small subset of sensory neurons marked by expression of the PROKR2Cre receptor. They determined that these neurons were three to four times more numerous in the deep fascia tissue of the hindlimb than in the fascia of the abdomen.

Then the team created mice that were missing these sensory neurons. They found that electroacupuncture in the hindlimb did not activate the vagal-adrenal axis in these mice. In another experiment, the team used light-based stimulation to directly target these sensory neurons in the deep fascia of the hindlimb.

This stimulation activated the vagal-adrenal axis in a manner similar to electroacupuncture. Basically, the activation of these neurons is both necessary and sufficient to activate this vagal-adrenal axis, Ma said.

In a final experiment, the scientists explored the distribution of the neurons in the hindlimb. They discovered that there are considerably more neurons in the anterior muscles of the hindlimb than in the posterior muscles, resulting in a stronger response to electroacupuncture in the anterior region.

Based on this nerve fiber distribution, we can almost precisely predict where electrical stimulation will be effective and where it will not be effective, Ma explained.

Together, these results provide the first concrete, neuroanatomic explanation for acupoint selectivity and specificity, Ma added. They tell us the acupuncture parameters, so where to go, how deep to go, how strong the intensity should be.

He noted that while the study was done in mice, the basic organization of neurons is likely evolutionarily conserved across mammals, including humans.

However, an important next step will be clinical testing of electroacupuncture in humans with inflammation caused by real-world infections such as COVID-19. Ma is also interested in exploring other signaling pathways that could be stimulated by acupuncture to treat conditions that cause excessive inflammation.

We have a lot of tough chronic diseases that still need better treatments, he said, such as inflammatory bowel syndrome and arthritis. Another area of need, he added, is excessive immune reactions that can be a side effect of cancer immunotherapy.

Ma hopes that his research will ultimately advance scientific understanding of acupuncture and provide practical information that can be used to improve and refine the technique.

Reference: A neuroanatomical basis for electroacupuncture to drive the vagaladrenal axis by Shenbin Liu, Zhifu Wang, Yangshuai Su, Lu Qi, Wei Yang, Mingzhou Fu, Xianghong Jing, Yanqing Wang and Qiufu Ma, 13 October 2021, Nature.DOI: 10.1038/s41586-021-04001-4

The work was primarily supported by the National Institutes of Health (grant R01AT010629), and partially supported by Harvard/MIT Joint Research Grants Program in Basic Neuroscience and the Wellcome Trust (grant 200183/Z/15/Z). For further information on salary support for the researchers, please refer to the paper.

Read more:
Harvard Neuroscientists Explore the Science of Acupuncture - SciTechDaily

Whats the connection between migraine headaches and military service? – Norton Healthcare

Jeremy Jackson has served five tours of duty in Iraq and Afghanistan. Over the years Jeremy has survived mortar blasts, roadside bomb attacks and a Humvee rollover. Now posted to Fort Knox, Kentucky, as an operations supervisor, Jeremy is one of many whose military service appears connected to headaches and migraine.

The Department of Veterans Affairs reports that veterans are more likely to experience migraine and headaches than non-veterans. Nearly a third of veterans who served a one-year deployment to Iraq were diagnosed with migraine or showed signs of the condition.

Jeremy started developing migraine after a roadside bomb attack in 2008. The issue got progressively worse, and by 2011, he experienced several migraine attacks per month.

Now, I average anywhere from one to three migraine [episodes] a week, and I have headaches every single day, he said. The only thing I can do is go lie down. When the migraine really kicks in, theres a tendency of getting cold sweats, the throbbing and all that in your head, and then it makes you nauseous, and then I start throwing up.

Brian M. Plato, D.O., headache neurologist with Norton Neuroscience Institute, is seeing more and more service members in the Norton Neuroscience Institute Headache Center.

We have a lot of veterans who are referred into our practice, and they all have very different, but similar stories, Dr. Plato said. Many had exposures to a direct head injury, or many of them are around a lot of blasts. I think a lot of people dont understand the consequences of being near a blast.

Many dont recognize that their brain was affected, so it can be months or years before they get treatment, according to Dr. Plato.

Our providers of migraine and headache care are now available with Norton Telehealth and shorter wait times for appointments.

Call (502) 899-6782

Over the past several years, new migraine medications have become available. Preventive treatments for migraine can include oral medications, monthly injections and Botox, which is done every three months. There also are medications that can ease the symptoms once a migraine strikes.

Jeremy, who also has been diagnosed with an acquired brain injury, takes medication and receives Botox for his migraine symptoms. The treatment helps, but the condition is still an issue for him.

With the Botox, I probably have one migraine a week instead of three or four, he said.

While the medication doesnt always stop a migraine once it starts, it often will prevent the nausea and vomiting.

Even with medications and current treatments, theres still no cure for migraine. But Dr. Plato is optimistic, as interest in the condition is growing.

I wish that I could say that there was some revolutionary treatment that was just around the corner, but that wouldnt be true, he said. Treatments that have been developed over the past several years are making researchers recognize that this is a condition with a high level of disability that affects many people. And so I think that youre going to see significant progress on this over the next five to 10 years.

For Jeremy and his fellow service members who experience migraine attacks, that progress cant come soon enough.

Fighting overseas, I never thought I would end up with an enemy in my own head, he said. And I know many others in the same boat. We just want it to get better.

Continued here:
Whats the connection between migraine headaches and military service? - Norton Healthcare